Pulmatrix Incis A Clinical Stage Biopharmaceutical Company Based In Lexingtonmassachusettsthe Company Specializes In Developing Inhaled Therapies Aimed At Treating Respiratory Diseases And Central Nervous System Disordersutilizing Its Proprietary Ispersea C Dry Powder Delivery Technologypulmatrix Focuses On Creating Targeted Pulmonary Treatments That Enhance Drug Efficacy And Improve Patient Outcomes The Company Is Advancing Several Novel Inhaled Therapeutics For Serious Conditions Such As Chronic Obstructive Pulmonary Diseasecopd Severe Asthmacystic Fibrosisand Acute Migrainesits Ispersea C Platform Formulates Smalldense Particles That Optimize Deep Lung Penetrationsupporting Both Small Molecule And Biologic Drugskey Products In Its Pipeline Include Pur1900An Inhaled Anti Fungal For Allergic Bronchopulmonary Aspergillosispur1800A Kinase Inhibitor For Copd Exacerbationsand Pur3100An Inhaled Formulation For Acute Migraine Treatmentpulmatrix Is Committed To Addressing Unmet Medical Needs In Chronic Respiratory Conditions And Migrainescollaborating With Healthcare Providers And Researchers To Further Its Clinical Programs
No conferences found for this company.
| Company Name | Pulmatrix Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
